Adam J. Townsend
CIK 1773588 · Chief Commercial Officer · last filed 2025-01-30
Adam J. Townsend is a Chief Commercial Officer who has filed 34 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider sold $20.5K of APLS on Jan 30, 2025. Across all open-market trades the lifetime net is −$13.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
34
-$13.31M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Commercial Officer | 84,050 | $41.03 | $3.45M | -$13.31M | 34 | 2025-01-30 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −695 | -$20.5K | EDGAR |
| 2025-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,323 | -$101.1K | EDGAR |
| 2025-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,201 | -$65.9K | EDGAR |
| 2025-01-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,685 | -$77.1K | EDGAR |
| 2024-02-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,148 | -$77.8K | EDGAR |
| 2024-01-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −906 | -$58.1K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,413 | -$221.8K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +21,513 | -$149.3K | EDGAR |
| 2023-12-05 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | — | -$5.03M | EDGAR |
| 2023-05-04 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | — | -$338.1K | EDGAR |